-
The NHS has decided not to fund lecanemab, an Alzheimer's drug approved by the UK regulator. The National Institute for Health and Care Excellence (NICE) concluded that the drug's benefits do not justify its costs, leaving patients to seek private treatment. This decision has sparked disappointment among patients and advocates.
-
The UK has approved lecanemab, an Alzheimer's drug developed by Eisai and Biogen, making it the first European country to do so. However, the National Health Service (NHS) is unlikely to fund it due to cost concerns, despite its efficacy in slowing cognitive decline.
-
Men taking sodium valproate are advised to use effective contraception due to a potential increased risk of neurodevelopmental issues in children conceived during treatment. The Medicines and Healthcare products Regulatory Agency (MHRA) issued this precautionary guidance following new evidence from Scandinavian studies.